Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Patients with a history of allergy to vitamin B or cobalt should not receive this injection
Retatrutide Phase 2 Obesity Trial: Efficacy and Safety at 48 Weeks New England Journal of Medicine Phase 2 trial in 338 adults with obesity showed retatrutide 12 mg produced 24.2% body weight loss at 48 weeks the highest reported for any anti-obesity pharmacotherapy with manageable GI side effects
Slow-myofiber commitment by semaphorin 3A secreted from myogenic stem cells
The injection is given just under the skin, similar to insulin injections that diabetics use daily
Sustainable weight loss outcomes Glp-1 medical weight loss allows patients to gradually adopt healthier habits, such as balanced eating and regular exercise
For more significant nausea, your healthcare provider may prescribe ondansetron (Zofran), metoclopramide (Reglan), or prochlorperazine (Compazine)
